Immune checkpoints could be key to treating autoimmune disease myasthenia gravis

(Kanazawa University) The PD-1 immune checkpoint is essential for self-recognition by the immune system, with disruption of the pathway associated with several autoimmune disorders. However, the involvement of PD-1 and its ligand PD-L1 in muscle-weakening autoimmune disease myasthenia gravis is unclear. Now, researchers at Kanazawa University have linked increased PD-L1 expression in the muscles of myasthenia gravis patients with disease severity and shown that this could ultimately help control the immune response and modulate disease symptoms.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Myasthenia Gravis (MG) – an autoimmune neuromuscular disease – is known by the production of autoantibodies against components of the neuromuscular junction mainly to the acetylcholine receptor, which cause the destruction and compromises the synaptic transmission. This disease is characterized by fluctuating and fati gable muscle weakness, becoming more intensive with activity, but with an improvement under resting. There are many therapeutic strategies used to alleviate MG symptoms, either by improving the transmission of the nerve impulse or by ameliorating autoimmune reactions with e.g.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Tags: Review Article Source Type: research
AbstractAryl hydrocarbon receptor (AhR), a type of transcriptional factor, is widely expressed in immune cells. The activation of AhR signaling pathway depends on its ligands, which exist in environment and can also be produced by metabolism. Normal expressions of AhR and AhR-mediated signaling may be essential for immune responses, and effects of AhR signaling on the development and function of innate and adaptive immune cells have also been revealed in previous studies. Recent studies also indicate that aberrant AhR signaling may be related to autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus eryth...
Source: Inflammopharmacology - Category: Drugs & Pharmacology Source Type: research
Myasthenia gravis (MG) is a neuromuscular autoimmune disease that affects the skeletal muscle through the production of autoantibodies against the nicotinic acetylcholine receptor at the neuromuscular junction, thus causing defective neuromuscular transmission in skeletal muscles [1]. MG occurs in 1: 7500 individuals, affecting women during the second to third decade and men in their fifth and sixth decade of life [2]. Typically, patients experience muscle weakness and fatigue, as well as fluctuating and fatigable extraocular (e.g.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Thymic tumors are rare diseases with an incidence of 0.15 cases per 100,000 person-years. They can be associated with a variety of other syndromes, such as Myasthenia Gravis or autoimmune disorders. Among them, pure red cell aplasia is a hemato-pathological condition characterized by anemia, reticulocytopenia and erythroid cell hypoplasia of bone marrow. Here, we reported a case of a 62-year-old female with a long history of neurologic symptoms due to Myasthenia Gravis. She was diagnosed with thymoma, with mediastinal mass and pleural thickening.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
This study aims to compare PLEX vs. IVIG in patients with MG.
Source: Archives of Physical Medicine and Rehabilitation - Category: Rehabilitation Authors: Source Type: research
This study aims to compare PLEX vs. IVIG in smokers with MG.
Source: Archives of Physical Medicine and Rehabilitation - Category: Rehabilitation Authors: Source Type: research
This study aims to compare PLEX vs. IVIG in patients with MG who have SLE/RA.
Source: Archives of Physical Medicine and Rehabilitation - Category: Rehabilitation Authors: Source Type: research
This article reviews the basic and advanced treatment options of the different disease subtypes including plasma exchange and immunoglobulins for treatment in a myasthenic crisis. Recently, clinical approval of eculizumab, a complement inhibitor, enriched the pharmacological armamentarium for AChR antibody-positive MG patients not appropriately responding to immunosuppression alone. PMID: 31538208 [PubMed - as supplied by publisher]
Source: Der Nervenarzt - Category: Neurology Authors: Tags: Nervenarzt Source Type: research
Myasthenia gravis (MG) is a rare and treatable antibody-mediated autoimmune disease. Pseudo internuclear ophthalmoplegia (-INO) or pyramidal tract damage is rarely observed in MG, and there were no known cases of MG with both pseudo-INO and pyramidal tract damage. Here, we report a case of a 61-year-old female suffering from MG accompanied by pseudo-INO and pyramidal tract damage with a rapid progressive course. Her blood and cerebrospinal fluid (CSF) tests were normal, except for the presence of the anti-acetylcholine receptor antibody. CT and contrast enhancement of the chest showed a thymic involution. MRI and contrast ...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Myasthenia gravis (MG) is an autoimmune disorder caused by antibodies targeting the neuromuscular junction, which in most cases are directed towards the skeletal muscle acetylcholine receptor (AChR) [1]. The pathophysiology of MG is accepted to be immune mediated [2]. Sporadic inclusion body myositis (IBM) is considered the most common inflammatory myopathy in patients over 50 years old, but its pathophysiology remains to this day an enigma: It is still unclear whether it is a primary degenerative disease with secondary dysimmune reaction or vice versa [3].
Source: Neuromuscular Disorders - Category: Neurology Authors: Tags: Case report Source Type: research
More News: Autoimmune Disease | Myasthenia Gravis